Sep 11, 2025 3:45 PM Eastern Daylight Time NASDAQ: LNTH: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Lantheus Holdings, Inc. Share RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus†) (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26 ...

Core Viewpoint - Lantheus Holdings, Inc. is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is being conducted by the Law Offices of Frank R. Cruz on behalf of investors [1] - The investigation follows the release of Lantheus's first quarter 2025 financial results on May 7, 2025 [1]

Core Viewpoint - Lantheus Holdings, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the performance and pricing of its key product, Pylarify, which has led to significant stock price declines [3]. Group 1: Legal Action - The Portnoy Law Firm is advising Lantheus investors who purchased securities between February 26, 2025, and August 5, 2025, to file a lead plaintiff motion by November 10, 2025 [1]. - Investors can contact attorney Lesley F. Portnoy for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations and Impact - The complaint claims that Lantheus and its executives misled investors about the growth and pricing strength of Pylarify, asserting that market leadership and premium pricing would support revenue growth while concealing competitive pressures [3]. - Following the release of quarterly results in May and August 2025, which showed sharp sales declines and reduced guidance, Lantheus' stock dropped over 23% and 28% respectively [3].

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Lantheus business and prospects, resulting in its stock trading at inflated prices. ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Lantheus Holdings, Inc. securities during the specified Class Period, alleging that the company made materially false and misleading statements regarding its product Pylarify, which led to investor damages when the truth was revealed [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 26, 2025, and August 5, 2025 [1]. - Investors who purchased Lantheus securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Lantheus provided overwhelmingly positive statements while concealing material adverse facts about Pylarify's competitive position, including its inability to assess pricing dynamics effectively [5]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by November 10, 2025, to represent the class in court [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased Lantheus securities between February 26, 2025, and August 5, 2025 [2]. Case Details - The Complaint alleges that Lantheus made materially false and misleading statements, including: - Providing overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The early 2025 price increase, despite prior price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and revenue [3]. - Defendants' statements regarding the Company's business and prospects were materially false and misleading [3]. Next Steps - Investors who suffered losses in Lantheus have until November 10, 2025, to request to be appointed as lead plaintiff in the case [4].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025. Lantheus describes itself as a "global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products.†For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. ...

Core Viewpoint - Lantheus Holdings, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims centered around misleading information regarding the company's revenue outlook and market dynamics for its key product, Pylarify [1][4]. Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products, particularly focusing on oncology, with Pylarify being a significant product used for prostate cancer diagnosis and treatment [3]. Allegations of the Lawsuit - The lawsuit claims that Lantheus executives misrepresented the company's revenue projections and downplayed risks related to competition, pricing, and macroeconomic factors [4]. - It is alleged that Lantheus's optimistic sales growth reports for Pylarify did not align with actual market conditions, leading to significant stock price declines following disappointing earnings reports [4][5]. Financial Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales, leading to a reduction in full-year growth projections from low-single-digit to flat-to-low single-digit percent growth, resulting in a stock price drop of over 23% [5]. - Following another disappointing announcement on August 6, 2025, which revealed an 8.3% year-over-year decline in Pylarify sales, the stock price fell nearly 29% [6]. Legal Process - Investors who purchased Lantheus securities during the specified class period (February 26, 2025, to August 5, 2025) have until November 10, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][7].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly providing misleading information to investors regarding the competitive position of its product Pylarify during the class period from February 26, 2025, to August 5, 2025 [1][2]. Group 1 - The lawsuit claims that Lantheus made overwhelmingly positive statements while concealing material adverse facts about Pylarify's competitive dynamics [2]. - It is alleged that the company was not adequately equipped to assess pricing and competition for Pylarify, which led to a risk of price erosion and affected revenue and growth potential [2]. - The complaint states that these misleading statements resulted in shareholders purchasing Lantheus securities at artificially inflated prices [2]. Group 2 - Investors who acquired shares of Lantheus are encouraged to contact the law firm before the lead plaintiff motion deadline on November 10, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation process [3].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly misleading investors regarding the competitive position of its key product, Pylarify, during the specified class period [1][2]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Lantheus made materially false and misleading statements about Pylarify's competitive position, failing to accurately assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not properly disclose the implications of a price increase in early 2025, which created opportunities for competitive pricing and risked Pylarify's revenue and growth potential [2][3]. Group 2: Financial Impact and Stock Performance - Following disappointing results announced on August 6, 2025, Lantheus reported an 8.3% year-over-year decline in Pylarify's performance and significantly reduced its growth projections for fiscal year 2025 [4]. - The announcement led to a sharp decline in Lantheus' stock price, dropping from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, representing a decline of approximately 28.8% in one day [4].